Login to Your Account



No hiatus for Kiadis: HSCT green light green-lighted

By Randy Osborne
Staff Writer

Monday, February 6, 2017

“I don’t think we had any real safety issue” with giving two doses in an earlier trial, noted Kiadis Pharma NV CEO Manfred Rüdiger, but Canadian phase III testing of ATIR101 will deploy a single dose of the treatment.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription